辛伐他汀对动脉瘤性蛛网膜下腔出血患者疗效的Meta分析  

Simvastatin for patients with aneurysmal subarachnoid hemorrhage：a Meta-analysis

作　　者：郭永涛[1] 李明超[1] 王丽君[1] 程谦涛[1] 

机构地区：[1]南京医科大学附属淮安第一医院神经内科,淮安223300

出　　处：《中华神经医学杂志》2016年第12期1235-1239,共5页Chinese Journal of Neuromedicine

摘　　要：目的系统评价辛伐他汀治疗动脉瘤性蛛网膜下腔出血患者的临床效果。方法计算机检索辛伐他汀用于动脉瘤性蛛网膜下腔出血的随机对照研究，检索时间从数据库各建库时间到2015年10月。由南京医科大学附属淮安第一医院神经内科的2位研究者独立评价纳入研究的质量、提取数据，统计分析采用RevMan5．1软件进行。结果纳入5项研究，共951例患者。Mere分析结果显示：辛伐他汀不能降低脑血管痉挛[相对危险度（RR）：1．26，95％置信区间（CI）：0．9-1．75，P=0．170]、迟发性脑缺血（RR=1．06，95％CI：0．88-1．26，P=-0．000）、不良预后（RR=1．05，95％CI：0．90-1．23，P=-0．540）发生率及死亡率（RR=0．95，95％CI：0．62～1．44，P=-0．800）。结论辛伐他汀不能够预防动脉瘤性蛛网膜下腔出血后血管痉挛、迟发性脑缺血及改善预后。Objective To evaluate the effectiveness ofsimvastatin for patients with aneurysmal subaraehnoid hemorrhage. Methods Systematic literature retrieval was carried out to obtain randomized controlled trials of simvastatin in patients with aneurysrnal subarachnoid hemorrhage before October 2015. Methodological quality assessment and data collection were performed by two individual reviewers. A Meta-analysis was performed by RevMan 5.1 software. Results Five studies, a total of 951 patients, were included. Meta-analysis showed that simvastatin could not reduce cerebral vasospasm （RR=1.26, 95% confidence interval [95%CI]： 0.9-1.75, P=0.170）, delayed cerebral ischemia （RR=1.06, 95%CI： 0.88-1.26, P=-0.000）, poor outcome （RR=1.05, 95%CI： 0.90-1.23, P=0.540）, or mortality （RR=0.95, 95%CI： 0.62-1.44, P=0.800）. Conclusion Simvastatin could not prevent cerebral vasospasm and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage, and could not improve the prognosis.

关 键 词：辛伐他汀 动脉瘤性蛛网膜下腔出血 META分析 

分 类 号：R743.35[医药卫生—神经病学与精神病学]